Loading...
Market
Performance of J&J Stock One Year After Proteologix Acquisition
4
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Stock market data and financial analysis reports
Story
Johnson & Johnson to Acquire Proteologix for $850 Million to Boost Immunology Portfolio
May 16, 2024, 12:25 PM
On May 16, Johnson & Johnson announced that it will acquire privately held, stealthy start-up Proteologix for $850 million in cash, with the potential for additional milestone payments. The acquisition aims to bolster Johnson & Johnson's position in the treatment of atopic dermatitis and other immunologic disorders. Proteologix brings a pipeline of bispecific antibodies, including a phase 1-ready TSLP/IL13 bispecific and experimental treatments for asthma and atopic dermatitis. This acquisition, which includes dual-targeting antibody drugs, is part of Johnson & Johnson's strategy to expand its immunology portfolio and is the latest M&A deal involving molecules addressing TSLP.
View original story
Similar markets
Decrease more than 10% • 25%
Decrease less than 10% • 25%
Increase less than 10% • 25%
Increase more than 10% • 25%
Significant gain in market share • 33%
Moderate gain in market share • 34%
No significant change in market share • 33%
Significant increase in J&J stock price • 33%
Moderate increase in J&J stock price • 34%
No significant change in J&J stock price • 33%
Yes • 50%
No • 50%
Stock Price Increases • 33%
Stock Price Decreases • 33%
Stock Price Remains Stable • 34%
Successful • 33%
Partially successful • 34%
Unsuccessful • 33%
Significant improvement • 25%
Moderate improvement • 25%
No significant change • 25%
Worsened financial performance • 25%
Approved • 50%
Not Approved • 50%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Significant increase in revenue • 25%
Moderate increase in revenue • 25%
No significant impact on revenue • 25%
Decrease in revenue • 25%